Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Apellis Pharmaceuticals stock

Learn how to easily invest in Apellis Pharmaceuticals stock.

Apellis Pharmaceuticals is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 476 staff and has a trailing 12-month revenue of around $113 million.

How to buy Apellis Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – APLS. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Apellis Pharmaceuticals stock price (NASDAQ: APLS)

Use our graph to track the performance of APLS stocks over time.

Apellis Pharmaceuticals shares at a glance

Information last updated 2023-01-24.
Latest market close$52.77
52-week range$33.32 - $70.00
50-day moving average $49.71
200-day moving average $52.43
Wall St. target price$74.88
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-7.87

Buy Apellis Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Apellis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Apellis Pharmaceuticals price performance over time

Historical closes compared with the close of $52.77 from 2023-01-27

1 week (2023-01-23) 4.27%
1 month (2022-12-30) 2.05%
3 months (2022-10-28) -12.92%
6 months (2022-07-29) -6.24%
1 year (2022-01-28) 36.75%
2 years (2021-01-29) 19.20%
3 years (2020-01-30) 27.13%
5 years (2018-01-30) 188.83%

Apellis Pharmaceuticals financials

Revenue TTM $113 million
Gross profit TTM $-253,920,000
Return on assets TTM -46.47%
Return on equity TTM -507.11%
Profit margin 0%
Book value $2.78
Market capitalisation $5.7 billion

TTM: trailing 12 months

Apellis Pharmaceuticals share dividends

We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.

Apellis Pharmaceuticals share price volatility

Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $33.32 up to $70. A popular way to gauge a stock's volatility is its "beta".

APLS.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.2264. This would suggest that Apellis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Apellis Pharmaceuticals overview

Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.

Frequently asked questions

What percentage of Apellis Pharmaceuticals is owned by insiders or institutions?
Currently 15.141% of Apellis Pharmaceuticals shares are held by insiders and 89.113% by institutions.
How many people work for Apellis Pharmaceuticals?
Latest data suggests 476 work at Apellis Pharmaceuticals.
When does the fiscal year end for Apellis Pharmaceuticals?
Apellis Pharmaceuticals's fiscal year ends in December.
Where is Apellis Pharmaceuticals based?
Apellis Pharmaceuticals's address is: 100 Fifth Avenue, Waltham, MA, United States, 02451
What is Apellis Pharmaceuticals's ISIN number?
Apellis Pharmaceuticals's international securities identification number is: US03753U1060
What is Apellis Pharmaceuticals's CUSIP number?
Apellis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 03753U106

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site